Introduction: The accurate diagnosis and monitoring of idiopathic Parkinson disease
symptoms in diagnosis is less than 90% (Weingarten, Sundman, Hickey, & Chen, 2015) . The Unified Parkinson Disease Rating Scale (UPDRS) score (Goetz et al., 2008) , the modified Hoehn-Yahr scale, and the Montreal Cognitive Assessment (MoCA) scale (Gill, Freshman, Blender, & Ravina, 2008) are commonly used to assess the disease progression and cognitive impairment in PD patients. Nevertheless, a lack of objectivity may result in uncertainty in evaluation. Therefore, there is an urgent need for imaging techniques that can provide an alternative objective evaluating approach.
Proton magnetic resonance spectroscopy ( 1 H-MRS) can give a neurochemical profile of the brain for individuals with PD by quantifying a range of metabolites including N-acetylaspartate (NAA), choline (Cho), and creatine (Cr) in different brain structures (Zanigni et al., 2015) . Normally, the Cr concentration is stable and can be used as reference when assessing NAA and Cho concentration (Lucetti et al., 2001) . Compared with healthy control subjects, PD patients showed reduced NAA/Cr ratio in the putamen (Watanabe et al., 2004) , and temporal lobe (Levin et al., 2014) and increased Cho/ Cr ratio in the posterior cingulate (Nie et al., 2013) , so these two variables could be used as metabolic markers to reflect the neuronal function in the PD brain. Furthermore, compared with the putamen and cerebral white matter, the changes of NAA/Cr ratio are proven to be more pronounced in the pontine base in PD patients than controls (Watanabe et al., 2004) . However, contradictory results for the NAA/
Cr ratio in the frontal cortex have been reported in parkinsonian syndromes subjects (Abe et al., 2000) . In addition, some studies showed no significant difference in Cho/Cr ratio in the lentifom nucleus between PD patients and healthy controls (Federico et al., 1997) , which may result from regional and individual variability or different signalto-noise ratio in different brain structures. Consequently, an overall description of the metabolic status in multiple regions of the brain is needed.
Previous studies have shown that the neurochemical profile produced with 1 H-MRS may provide useful information for the diagnosis, monitoring, and evaluation of treatment efficacy in PD. A randomized permuted block study (Mazuel et al., 2015) comparing patients with PD in drug-on and drug-off conditions and healthy controls found that total NAA and Cr were significantly lower in drug-off patients than controls and further, the two biomarkers increased after dopaminergic therapy. In addition, MRS studies showed that PD involved widespread neuronal and axonal damage.
Moreover, Wu et al. (2016) suggested a more notable change in NAA/Cr on the side affected at the onset of PD, which may be a reasonable interpretation to the asymmetric symptoms and signs in PD patients.
Given the background, we used a multi-voxel 1 HMR spectroscopic approach to provide a neurochemical profile of multiple regions of the idiopathic PD brain. We also recorded the UPDRS score, modified Hoehn-Yahr stage, and the MoCA score of PD patients.
This study aimed to assess the relationship between the NAA/Cr, NAA/Cho and Cho/Cr ratio and UPDRS score, Hoehn-Yahr stage and
MoCA score in PD patients to assess the value of 1 H-MRS in early diagnosis of the disease and evaluation of cognitive ability of PD patients. Water suppression (>95%) and shimming (linewidth, <12 Hz)
| MATERIALS AND METHODS

| Subjects
| MR imaging and
1
H-MRS
were automatically achieved using a variable pulse power and optimized relaxation delay scheme. After zero-filling and baseline correction, the spectra were post-processed automatically using "Advantage Window 4.6 workstation Functool software" (General Electric Medical Systems Signa excite 3.0T HD Ecospeed MRI, ADW 4.6 workstation, USA). The peak areas were the proportion using creatine as the reference which represent the various metabolic concentration such as NAA/Cr and Cho/Cr. The regions of interest (ROIs) for spectral analysis included the substantia nigra, globus pallidus, prefrontal lobe, hippocampus, cuneus gyrus and dorsal thalamus on both sides of the brain (Figure 1 ).
| MRS analysis
All spectra were transferred to an Advantage Window 4.6 workstation (GE, ADW 4.6 workstation, USA) and were processed using Functool (General Electric Medical Systems, USA). The metabolite signal intensity for NAA, Cho, and Cr were 2.02, 3.22 and 3.02 ppm, respectively. Examples of spectra are presented in Figure 2 . Because of no significant differences between the left and right hemisphere for control and bilateral impaired PD patients and between the side contralateral and ipsilateral to for unilateral impaired PD patients, the values obtained for each side were averaged to represent the metabolism level for each participant (for NAA/Cr ratio, see Figure 3 ;
for NAA/Cho and Cho/Cr ratios, see Figure S1 and Figure S2 online, respectively).
| Statistical analysis
Quantitative data are presented as mean (SD), and categorical data as number (% vs. 29.59 ± 9.29, respectively; p = .011). The baseline characteristics of the cases are in Table 1 .
The NAA/Cr, NAA/Cho, and Cho/Cr ratios for cases and controls in multiple regions are summarized in Table 2 . Overall, NAA/Cr and
The regions of interest location on 1 H-MRS images (1, 2), dorsal thalamus (3, 4), globus pallidus (5, 6), substantia nigra (7, 8), hippocampus (9, 10), cuneus gyrus (11, 12)
H-MRS spectra obtained from a control subject (a) and a PD patient (b) NAA/Cho ratios were significantly lower in the substantia nigra, globus pallidus, prefrontal lobe, hippocampus, cuneus gyrus, and dorsal thalamus regions for total cases than healthy controls and lower in the six regions for both unilateral and bilateral impaired patients than controls, with no difference between unilateral and bilateral impaired PD patients (all p > .05).
Compared to controls, patients with mild or no cognitive impairment showed significantly reduced NAA/Cr ratios in substantia nigra, globus pallidus, hippocampus, and dorsal thalamus regions ( Figure S1 ), whereas the NAA/Cho were lower in globus pallidus, cuneus gyrus, and dorsal thalamus regions. Patients with cognitive impairment showed significantly reduced NAA/Cr and NAA/Cho ratios in all six regions of interest, with no difference between cognitive and mild or no cognitive impairment patients (all p > .05).
Cho/Cr ratios in the cuneus gyrus were higher for all PD patients than control subjects. The differences were even greater in the dorsal thalamus and remained significantly different on stratification by Hoehn-Yahr stage or MoCA score.
We observed modest but significant relationship between UPDRS score and NAA/Cho ratio in the substantia nigra (r = −.42; p = .006), globus pallidus (r = −0.37; p = .017), hippocampus (r = −.36; p = .021), and cuneus gyrus (r = −.38; p = .013). In addition, UPDRS score and 
| DISCUSSION
In thisstudy, we used a multi-voxel 1 H-MR spectroscopic approach to describe a neurochemical profile in multiple regions of the PD brain.
NAA/Cr and NAA/Cho ratios were lower in the substantia nigra, globus pallidus, prefrontal lobe, hippocampus, cuneus gyrus and dorsal thalamus regions of the brain of PD patients than healthy controls, which indicates widespread neuronal and axonal damage in the PD brain. Besides, NAA/Cr and NAA/Cho ratios were lower in PD patients with unilateral or mild/no cognitive impairment than controls, which suggests that those two metabolites might be early diagnostic biomarkers of PD and sensitive biomarkers of cognitive impairment in PD. In addition, NAA/Cr ratios in the prefrontal lobe and cuneus gyrus and NAA/Cho ratios in the substantia nigra, prefrontal lobe and hippocampus might indicate severity of cognitive impairment. We found NAA, N-acetylaspartate; Cho, choline; Cre, creatine; SN, substantia nigra; GP, globus pallidus; PL, prefrontal lobe; HI, hippocampus; CG: cuneus gyrus; DT, dorsal thalamus. The data are presented as median (interquartile range).*p < .05, **p < .01, ***p < .001, compared with controls.
high Cho/Cr ratios in the dorsal thalamus of PD patients. Moreover, the significant inversely correlation between UPDRS score and NAA/ Cho ratios in the substantia nigra, globus pallidus, hippocampus, and cuneus gyrus and NAA/Cr ratios in the substantia nigra implying that those two metabolites from corresponding brain regions might be used to monitor pathologic changes in patients with PD. Specifically, reduced NAA level may represent reduced number of neurons or neuron deficiency, whereas a decreased NAA level reflects severe neurodegeneration and motor impairment (Sharma et al., 2013) . Our results agree with previous researches, and the biomarker changes in PD patients in our study could point to neuronal loss or degeneration or neural mitochondrial dysfunction in the PD brain.
Although some studies found differences between the side ipsilateral and contralateral to clinical signs in PD patients with unilateral impairment, our study did not find significant differences between the contralateral and ipsilateral sides in multiple regions of the PD brain, and no significant differences between the left and right hemispheres in controls or bilateral impaired patients. The reason could be explained by the prior existence of pathologic changes to clinical symptoms. In addition to that, our results agree with previous studies (Mazuel et al., 2015) . Besides, reduced NAA/Cr, and NAA/Cho ratios and increased reduced NAA/Cr ratio in the temporoparietal cortex (Hu et al., 1999) and motor cortex (Lucetti et al., 2001) . However, there are single-
H-MRS gave conflicting results, which failed to demonstrate significant NAA/Cr ratio change in the striatum (Holshouser et al., 1995) and significant NAA/Cho ratio change in the occipital cortices (Tedeschi et al., 1997) . The discrepancy can be explained in part by the difference in study population and sample size and the region of interest in previous studies. Further studies are needed to address this issue.
On the analysis stratified PD patients to unilateral and bilateral PD patients, there are differences in NAA/Cr and NAA/Cho ratios between PD patients with unilateral and bilateral impairment, and controls but not between unilateral and bilateral impairment patients.
The fact that the Hoehn-Yahr stage of our bilateral PD patients group ranged from 2 to 3 and treatment of PD might explain this absence of significant difference. The MoCA scale is a sensitive and brief test that
can be used to screen mild cognitive impairment (Dalrymple-Alford et al., 2010). When stratified PD patients into cognitive impairment and mild/no cognitive impairment, our results showed that NAA/Cr and NAA/Cho ratios were lower for our patients with mild/no cognitive impairment than healthy control subjects. Since the NAA/Cr ratios in the prefrontal lobe and cuneus gyrus and the NAA/Cho ratios in the substantia nigra, prefrontal lobe and hippocampus were statistically significant reduced in cognitive impairment but not mild/no cognitive impairment than controls, those information might be used to detect the severity of cognitive impairment. Additionally, previous observations showed that clinical symptoms will not appear until patients show >60% dopaminergic neuron loss, our results highlight the change in NAA/Cr and NAA/Cho ratios for patients with mild/no cognitive impairment and provide evidence of prior existence of the neurochemical changes to cognitive function in PD.
NAA/Cho ratios in the substantia nigra, globus pallidus, hippocampus, and cuneus gyrus and NAA/Cr ratios in substantia nigra were inversely correlated with the UPDRS score. The relatively weak correlation may due to the relatively small variations in UPDRS scores in our study population. However, our results are in keep with previous investigations (Wu et al., 2016) and the significant inverse relationship between the NAA/Cho and NAA/Cr ratios and the UPDRS score suggests that the reduction NAA/Cho and NAA/Cr ratios might be associated with advanced PD and thus, more pronounced neuronal damage. some studies found no changes in the frontal lobe (Abe et al., 2000; Watanabe et al., 2004) and others reported decreased Cho/Cr ratios in the temporoparietal cortex in PD patients (Taylorrobinson et al., 1999) . Technical factors and different regions of interest could be possible explanations, and further 1 H-MR spectroscopic study is needed.
| SUMMARY
PD has become a major public health problem worldwide and mostly affects the aging population. 
